U.S. Markets closed

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.350.00 (0.00%)
At close: 4:00PM EDT
People also watch
AVXLCURONCSADXSBCLI
  • k
    ken
    ken
    Well now. Our CEO did a good job at the presentation.
  • B
    Biotrader922
    Biotrader922
    New corp presentation. Submission for Inspire now not slated until 2019.

    Another year of pay...good work Perrin LMAO
  • C
    Chris
    Chris
    Here will be a moment of truth for MP. He will either stun with some great news or he will have nothing but the same old same old. Share price seems to expect very little from the slacker. Sad to say, I don't expect much either. We've all seen enough of him to know he's a terrible leader.
  • F
    Fabio
    Fabio
    Nobody here is following the online conference?
  • J
    Jack
    Jack
    I was listening to the presentation and it stopped at 16:30 just when Perin was getting to the important information regarding the status of the study. Anyone else have this problem?
  • D
    Dude
    Dude
    Mark Perrin, milquetoast extraordinaire and "little league" peter-principled CEO, never fails to underwhelm. Why is he even attending this event? He had how many weeks to sharpen up the plan? If people were on a deserted island with this clown, NOBODY better follow his directions to survive! In fact, build a raft and let him look for land past the horizon (assuming no stranded cannibals who might hold value in his flesh). What a waste of oxygen!
  • S
    Steve
    Steve
    One thing we is for sure. The next company he becomes the CEOSHORT THE #$%$ OUT OF IT!!!!!!!!!!!!!!
  • J
    Jnsnintrcptr
    Jnsnintrcptr
    You all know me as a solid long. I'm still holding but just sold tons of my shares! Breaks my heart I'll come back.
  • J
    Jnsnintrcptr
    Jnsnintrcptr
    Who is the one person on the planet the benefits tremendously by the study being voluntarily halted causing a huge delay. It would be the person that volunteered to halt the study!
    Part of me feels like we are being completely used and milked by MP!
  • G
    Gary
    Gary
    i see they got the lunch time slot at the conference tomorrow ... will anyone be there? are they providing free hoagies for those who show up?
  • S
    Steve
    Steve
    Just when you thought MP could not deliver bad news HE DOES
    1. Halt the study
    2. Warrants
    3. Layoffs
    4.Submission
    I will give you 5 and 6
    5. The guy makes 1.9 million a year
    6. Not selling your house in 5 years in a sellers market
    Number 6 is the tell
  • A
    ANDREAS
    ANDREAS
    I wonder if some of the shorts are hitting the exit doors? Tomorrow may be too late. We shall see! Good luck
  • k
    ken
    ken
    The upcoming investor conference is a forum for financial planners, economists, market analysts, economists, accountants and bankers. Will NVIV be able to toss the tired old slide presentation in favor of a new one aimed at the proper audience? Will the audience learn what an investment in NVIV can produce in 1, 2, 3 years? Will they learn about the risk of success and failure? Will they learn about PW of future net income under various assumptions? Will they learn about how/when NVIV will restart the trial? What about the trial has changed if anything? What are the updated results on conversions? What can be said about a marketing plan? How does the scaffold stack up sise-by-side with stem cell science/results?
  • L
    La
    La
    seems like NVIV is green every day lately. Who can explain this phenomenon?
  • B
    Biotrader922
    Biotrader922
    Invivo's beloved Jnap found guilty by the SEC wwwDOTsecDOTgov/litigation/litreleases/2017/lr23943DOThtm
  • D
    David
    David
    Here's the deal with this company. They are fast tracked by the FDA to only enroll 20 patients in their INSPIRE program and get a 25% improvement rate 6 months after the procedure has been completed. In the end of July, the company announced that patient 17 passed away which made every headline regarding this company. However, people did not actually read the article. Although patient 17 passed away, it was proven by an outside investigation that it had nothing to do with the device or the procedure. They also reported that after 6 months, 11 patients have reported back and 6/11 (54.5%!!) have improved after a half of a year. What makes this number even more interesting is that 6/20= 30%. Therefore, if none of the last 9 patients report improvements after 6 months, the company already met the threshold the FDA set for them. All that needs to be done is resume the program and get the last of the four patients enrolled and FDA approval is here! My price target by end of December is $9. I am currently very bullish, but it will be a long ride ahead of us.
  • c
    creedheed
    creedheed
    16 evaluable patients in 41 months and now they re going to be "much more cautious" about enrolling the last 4 patients. But why not MORE selectivity, ahem. You can't make this #$%$ up. Or can they? And what happened to the COMPANY halting the trial? In today's presentation he clearly states the FDA and the data safety monitoring board decided to pause in an "abundance of caution." Only thing in abundance around this trial is the BS. "Are we enrolling patients who just are at a high risk of dying?" They're complete SCI patients for pete's sake! Duh
  • m
    mark
    mark
    Hey I like it !! i am sitting in London thinking wow NVIV !
    I can't wait to get home to Boston and see NVIV at $2.75 in Oct! good thoughts to all inflicted ....this will work out in our favor !
  • A
    ANDREAS
    ANDREAS
    Looks like we will be getting an update on 26sept! Hopefully it will be Good News! Gluck to all longs!
  • F
    Fabio
    Fabio
    That's what we long are waiting for, I believe, and I hope that we are meeting with the FDA for the resumption of the study but also to clarify whether the FDA has accepted as the control arm proposed by Nviv and if the endpoint is confirmed to 25% of 20 patients